BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP- 812 Aspa’s Investigational Gene Therapy for Canavan Disease
Go Back BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP- 812 Aspa’s Investigational Gene Therapy for Canavan Disease 10 September 2024 We’re thrilled to announce that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BBP-812, Aspa’s investigational AAV9 gene therapy for Canavan disease. We are committed to working closely […]
